

Bedside clinical data provide an hourly and accurate biomarker for severe sepsis classification

Jacquelyn Dawn Parente^a, GM Shaw^b, J Lin^c, JG Chase^a

^aUniversity of Canterbury, ^bChristchurch Hospital, ^cUniversity of Otago Christchurch

Severe sepsis is common, deadly & costly

Severe sepsis is organ failure and SIRS due to infection [1].



NZ and AUS ICU [2]

11.8% incidence

0.77 per 1000 prevalence


26.5% mortality

6x treatment cost [3]

\$16.7B USD total cost [4]

A need for real-time diagnostics

Sepsis severity increases with concurrent





However, **hierarchical** criteria fails when physiological responses are resolved, yet the underlying infection remains. Thus, to enable hour-to-hour sepsis classification, we examined the diagnostic performance of a continuous sepsis score, where each category was scored **independently**, rather than hierarchically.

Classification using bedside data


A severe sepsis biomarker was developed from:

- 36 patients at the Christchurch Hospital ICU
- 6550 hours (**1690 severe sepsis**, **4860 non-severe sepsis**)
- insulin sensitivity, temperature, heart & respiratory rate, MAP, SIRS

Kernel density estimates were used for classification [6]. A ROC curve was used to determine diagnostic performance.








High accuracy and high negative prediction



The biomarker correctly identifies 84% of severe sepsis and 85% of non-severe sepsis hours. A 0.91 Area Under the Curve shows high accuracy [7]. The test also provides high Negative Predictive Value to rule-out infection.

This novel biomarker is readily accessible, highly accurate, and provides a real-time diagnostic for severe sepsis



References

1 Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM consensus conference committee. *Chest* 101:1644-1655. **2** Finfer S, Bellomo R, Lipman J, French C, Dobb G, Myburgh J (2004) Adult-population incidence of severe sepsis in Australian and New Zealand intensive care units. *Int Care Med* 30:589-596. **3** Edbrooke DL, Hibbert CL, Kingsley JM, Smith S, Bright NM, Quinn JM (1999) The patient-related costs of care for sepsis patients in a United Kingdom adult general intensive care unit. *Crit Care Med* 27(9):1760-1767. **4** Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR (2001) Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. *Crit Care Med* 29:1303-1310. **5** Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G (2003) 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. *Crit Care Med* 31:1250-1256. **6** Hastie T, Tibshirani R, Friedman JH (2001) *Elements of Statistical Learning: Data Mining, Inference and Prediction*. Springer, New York. **7** Fischer JE, Bachmann LM, Jaeschke R (2003) A readers' guide to the interpretation of diagnostic test properties: clinical example of sepsis. *Int Care Med* 29:1043-1051.

Acknowledgments

Thank you Christchurch Hospital for ongoing research collaborations. Travel funding was provided in-part by the University of Canterbury Department of Mechanical Engineering.



Contact

jacquelyn.parente
@pg.canterbury.ac.nz